<li data-leveltext="o" data-font="Courier New" data-listid="13" data-list-defn-props="{"335552541":1,"335559684":-2,"335559685":1440,"335559991":360,"469769226":"Courier New","469769242":[9675],"469777803":"left","469777804":"o","469777815":"hybridMultilevel"}" aria-setsize="-1" data-aria-posinset="1" data-aria-level="1"> Covid-19 vaccine <li data-leveltext="o" data-font="Courier New" data-listid="13" data-list-defn-props="{"335552541":1,"335559684":-2,"335559685":1440,"335559991":360,"469769226":"Courier New","469769242":[9675],"469777803":"left","469777804":"o","469777815":"hybridMultilevel"}" aria-setsize="-1" data-aria-posinset="1" data-aria-level="1"> Vaccines other than covid-19

Science & Technology

BGP as a global biopharmaceutical company has established a cutting-edge R&D lab for the development of mRNA vaccines and therapeutics.

The mission of the mRNA R&D lab is to develop safe and effective mRNA-based vaccines and therapies for a wide range of diseases and conditions.

BGP’s experienced team of scientists and researchers is dedicated to pushing the boundaries of mRNA technology to the full potential to revolutionize disease prevention and treatment.

The R&D lab is equipped with state-of-the-art equipment and facilities, enabling us to conduct a wide range of experiments and tests. We utilize the latest technologies and methods to develop and optimize our mRNA-based therapies, ensuring that they are safe, effective, and scalable.

Infectious diseases

Covid-19 vaccine
Vaccines other than covid-19

mRNA platform

While there are currently no available mRNA vaccines in low- and middle-income countries other than COVID-19, ongoing research and development in this area will ultimately lead to pioneering and affordable vaccines in the world’s emergency situations.

mRNA as advance therapy medicinal products (ATMP)

In addition to vaccines, other areas such as cancer therapeutics and gene editing are under evaluation utilizing mRNA platform capabilities.

Sharing Expertise

Sharing expertise and knowledge with the hub members which can accelerate the mRNA vaccine and therapeutics development.

Manufacturing Processes

Working with the hub and other spokes in optimizing the manufacturing process which can help in bringing vaccines.

Contributing to Clinical

Contribute to clinical trials design and execution with hub members, which can enhance the clinical trials efficiency.

Data Analysis

Sharing in the data analysis of the development experiments and trials identifying patterns and trends that can help .

Building Capacity

Building the capacity for mRNA hub by giving training and technical assistance to other spokes.

Regulatory Affairs

Recognizing the importance of navigating regulatory pathways for the approval and distribution of vaccines and therapies.

We’re running business since 2020

BGP collaborates with leading global partners including the world health organization (WHO), medicines patent pool (MPP), institutions and industry partners to bring our developed vaccines and therapies to patients as quickly as possible.

The R&D lab at BGP as one of the spokes of mRNA technology transfer hub programme, is aiming at:
• Sharing expertise and knowledge with the hub members which can accelerate the mRNA vaccine and therapeutics development.
• Working with the hub and other spokes in optimizing the manufacturing process which can help in bringing vaccines and therapeutics to the market faster.
• Contribute to clinical trials design and execution with hub members, which can enhance the clinical trials effectiveness and efficiency.
• Sharing in the data analysis of the development experiments and trials identifying patterns and trends that can help in shaping the future development efforts.
• Building the capacity for mRNA hub by giving training and technical assistance to other spokes.

Let’s discuss your project with Our BGP team

BGP’s major tasks and challenges are the development to discover novel patented products. Continuing and reinforcing the investment in R&D for creation of novel products and biosimilar development to be an effective WHO mRNA technology transfer partner and hub. Reinforcing the in-licensing policy, especially in the Middle East & Africa region through agreements with the world’s leading companies.